EUVIMEDEUVIMED entdecken
Crossref

Immunotherapy unleashed: pioneering chemo-free neoadjuvant programmed cell death ligand 1 (PD-L1) inhibition for resectable non-small cell lung cancer (NSCLC)

Nikki E. Rossetti, Varun Puri

AME Clinical Trials Review · 2024

DOI: 10.21037/actr-23-34 ↗

Kurz gefasst

Fachartikel in der Zeitschrift AME Clinical Trials Review, 2024. Verfasst von Nikki E. Rossetti und 1 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Rossetti, N. E., & Puri, V. (2024). Immunotherapy unleashed: pioneering chemo-free neoadjuvant programmed cell death ligand 1 (PD-L1) inhibition for resectable non-small cell lung cancer (NSCLC). AME Clinical Trials Review. https://doi.org/10.21037/actr-23-34

Vancouver

Rossetti NE, Puri V. Immunotherapy unleashed: pioneering chemo-free neoadjuvant programmed cell death ligand 1 (PD-L1) inhibition for resectable non-small cell lung cancer (NSCLC). AME Clinical Trials Review. 2024. doi:10.21037/actr-23-34

BibTeX
@article{Rossetti2024,
  author = {Rossetti, Nikki E. and Puri, Varun},
  title = {Immunotherapy unleashed: pioneering chemo-free neoadjuvant programmed cell death ligand 1 (PD-L1) inhibition for resectable non-small cell lung cancer (NSCLC)},
  journal = {AME Clinical Trials Review},
  year = {2024},
  doi = {10.21037/actr-23-34}
}
Kostenlos starten →